Cooper Companies Inc
F:CP6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cooper Companies Inc
F:CP6
|
US |
|
C
|
Carnival PLC
OTC:CUKPF
|
UK |
|
Q
|
Quest Diagnostics Inc
LSE:0KSX
|
US |
|
EMCOR Group Inc
NYSE:EME
|
US |
|
A
|
American Electric Power Company Inc
XBER:AEP
|
US |
|
Triple Flag Precious Metals Corp
NYSE:TFPM
|
CA |
|
C
|
Cigna Corp
XETRA:CGN
|
US |
Cooper Companies Inc
Cooper Companies makes medical products in two main areas: contact lenses and women’s health. Through CooperVision, it sells soft contact lenses for nearsightedness, farsightedness, astigmatism, and presbyopia to eye doctors, optometrists, retailers, and patients. Through CooperSurgical, it sells tools and devices used by fertility clinics, hospitals, and other women’s health providers. The company makes money by manufacturing these products and selling them to healthcare professionals and distributors. A large part of its business comes from recurring use: contact lenses are replaced regularly, and many of its surgical and fertility products are used in ongoing clinical procedures. That gives Cooper a mix of everyday consumer-style demand and professional healthcare demand. What makes Cooper’s business different is that it sits in two specialized niches with long-term customer relationships. In vision care, it focuses on products people need to wear every day, while in women’s health it supplies equipment and consumables used in clinics and hospitals. That combination gives the company a steady role in both routine eye care and specialized medical procedures.
Cooper Companies makes medical products in two main areas: contact lenses and women’s health. Through CooperVision, it sells soft contact lenses for nearsightedness, farsightedness, astigmatism, and presbyopia to eye doctors, optometrists, retailers, and patients. Through CooperSurgical, it sells tools and devices used by fertility clinics, hospitals, and other women’s health providers.
The company makes money by manufacturing these products and selling them to healthcare professionals and distributors. A large part of its business comes from recurring use: contact lenses are replaced regularly, and many of its surgical and fertility products are used in ongoing clinical procedures. That gives Cooper a mix of everyday consumer-style demand and professional healthcare demand.
What makes Cooper’s business different is that it sits in two specialized niches with long-term customer relationships. In vision care, it focuses on products people need to wear every day, while in women’s health it supplies equipment and consumables used in clinics and hospitals. That combination gives the company a steady role in both routine eye care and specialized medical procedures.
Revenue: Consolidated Q1 revenue $1.024 billion, up 6.2% year-over-year (up 2.9% organically); CooperVision $695 million, CooperSurgical $329 million.
Profitability: Q1 gross margin 68.1% and non-GAAP EPS $1.10 (up 20%); operating income improved and operating margin reached 26.9%.
Cash & capital: Q1 free cash flow $159 million with CapEx $102 million; repurchased $92 million of stock and reduced net debt to $2.4 billion.
Guide raise: Management raised EPS guidance to $4.58–$4.66 and increased fiscal 2026 free cash flow guide to $600–$625 million; revenue guidance largely unchanged at $4.30–$4.35 billion.
Demand trends: MyDay portfolio and MiSight drove strength (MiSight +23%); Americas and EMEA showing momentum, Asia Pac pressured by Japan legacy hydrogel decline but expected to recover by fiscal Q3.
Operational actions: Reorganization and IT/AI investments are delivering durable cost synergies; management is reinvesting some savings into sales/marketing and product launches.
Strategic review: Board-led strategic review is ongoing; no definitive update provided but management continues normal operations (buybacks, debt paydown, reinvestment).
